BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
48.235 EUR
+0.46 (+0.97%)
BRM gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 53 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally BRM also has an excellent dividend rating. These ratings could make BRM a good candidate for value and dividend investing.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
In the past year BRM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BRM (6.23%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 32.55%, BRM belongs to the top of the industry, outperforming 81.13% of the companies in the same industry.
BRM's Return On Invested Capital of 16.42% is fine compared to the rest of the industry. BRM outperforms 77.36% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.02%.
The last Return On Invested Capital (16.42%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM's Profit Margin of 12.57% is in line compared to the rest of the industry. BRM outperforms 50.94% of its industry peers.
BRM has a Operating Margin of 33.51%. This is amongst the best in the industry. BRM outperforms 83.02% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
BRM has a better Gross Margin (73.15%) than 60.38% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.25. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM has a Altman-Z score (2.25) which is in line with its industry peers.
BRM has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as BRM would need 3.20 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.20, BRM is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
A Debt/Equity ratio of 2.41 is on the high side and indicates that BRM has dependencies on debt financing.
BRM's Debt to Equity ratio of 2.41 is on the low side compared to the rest of the industry. BRM is outperformed by 81.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.25 |
ROIC/WACC1.94
WACC8.47%
2.3 Liquidity
A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
BRM has a Current ratio (1.27) which is comparable to the rest of the industry.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
BRM's Quick ratio of 1.17 is fine compared to the rest of the industry. BRM outperforms 67.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 460.68%, which is quite impressive.
Measured over the past years, BRM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 1.26%.
Measured over the past years, BRM shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 35.29% on average per year.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.06% yearly.
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-5.06%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated reasonably with a Price/Earnings ratio of 8.60.
90.57% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.25), we can say BRM is valued rather cheaply.
BRM is valuated reasonably with a Price/Forward Earnings ratio of 9.30.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 88.68% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.98. BRM is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.6 | ||
| Fwd PE | 9.3 |
4.2 Price Multiples
BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 90.57% of the companies in the same industry.
100.00% of the companies in the same industry are more expensive than BRM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.5 | ||
| EV/EBITDA | 6.91 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y130.59%
EPS Next 3Y73.3%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 4.51%, which is a nice return.
BRM's Dividend Yield is rather good when compared to the industry average which is at 1.72. BRM pays more dividend than 86.79% of the companies in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.51% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
FRA:BRM (1/13/2026, 4:27:57 PM)
48.235
+0.46 (+0.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap98.19B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts70
Price Target47.16 (-2.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.51% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.81%
PT rev (3m)6.62%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)5.91%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)1.97%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.6 | ||
| Fwd PE | 9.3 | ||
| P/S | 2.39 | ||
| P/FCF | 7.5 | ||
| P/OCF | 6.91 | ||
| P/B | 6.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.91 |
EPS(TTM)5.61
EY11.63%
EPS(NY)5.18
Fwd EY10.75%
FCF(TTM)6.43
FCFY13.33%
OCF(TTM)6.98
OCFY14.48%
SpS20.18
BVpS7.79
TBVpS-9.94
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.25 |
F-Score6
WACC8.47%
ROIC/WACC1.94
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-5.06%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.97%
EBIT Next 3Y49.92%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 478.44% in the next year.
Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?
The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 8 / 10 and the dividend payout ratio is 82.81%.